linjc16/ctgov huggingface dataset:
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients

Study Overview
=================
Brief Summary
-----------------
80% of patients with alcohol use disorders (AUD) present cognitive impairments, such as memory and executive functions. These disorders may have repercussions in addiction treatment by altering the patient's adherence to care. The level of impairment is dependent on the onset of addiction, and also the duration of abstinence. A complete neuropsychological evaluation is necessary to highlight cognitive impairments. In practice, the evaluation of these disorders by practitioners, is done with the help of tools of screening like the MoCa (Montreal cognitive assesment) and the BEARNI (Brief evaluation of alcohol related neuropsychological impairment). However, none of these tools have been evaluated in patients with alcoholic cirrhosis. Indeed, some studies have suggested that liver disorders including cirrhosis may be a factor aggravating cognitive disorders. The purpose of this study is to evaluate the ability of the BEARNI tool to detect alcohol-related cognitive problems in patients with alcohol-related cirrhosis.

Official Title
-----------------
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients

Conditions
-----------------
Alcohol Dependence, Dependence, Cognitive Impairments, Cirrhosis, Liver Diseases

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with cirrhosis patients with cirrhosis diagnosed by clinical examination patients with cirrhosis diagnosed by biological and / or morphological and / or noninvasive tests and / or liver biopsy CHILD A, B or C Exclusion Criteria: hepatitis encephalopathy less than 6 months old complicated cirrhosis with hepatocellular carcinoma Acute alcoholic hepatitis viral cirrhosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|AUDIT questionnaire (alcohol use disorders identification test)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders | the number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders will be measured by using the BEARNI screening tool. BEARNI screening tool is Brief evaluation of alcohol related neuropsychological impairment. | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alcohol Dependence, Dependence, Cognitive Impairments, Cirrhosis, Liver Diseases
Meaning-Centered Psychotherapy in Advanced Cancer

Study Overview
=================
Brief Summary
-----------------
We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.

Detailed Description
-----------------
As per Brief Summary

Official Title
-----------------
Meaning-Centered Psychotherapy in Advanced Cancer

Conditions
-----------------
Lymphoma, Non-Hodgkin, Neoplasms

Intervention / Treatment
-----------------
* Behavioral: Meaning-Centered Group Psychotherapy
* Behavioral: Standard Supportive Group Psychotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 21 years of age or older; English speaking; Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma; Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City; Exclusion Criteria: Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention; Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent; Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Meaning-Centered Group Psychotherapy|nan|
|Behavioral: Standard Supportive Group Psychotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stage 3 cancer;, Stage 4 cancer;, solid tumor cancer;, Non-Hodgkin's Lymphoma;, solid tumors;, end-stage cancer;, group psychotherapy;, psychotherapy;, emotional support;, support groups
Prognostic Factors of Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Official Title
-----------------
Prognostic Factors of Patients With COVID-19

Conditions
-----------------
SARS-CoV-2, Outcome, Fatal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged >=18years old; Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia. Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg. Exclusion Criteria: Near-death state (expected survival time less than 24 hours); Malignant tumor; Pregnancy or puerperium women; Patients who refused to participant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality |  | 15 days | 
| Severe state | Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg. | 15 days |
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Study Overview
=================
Brief Summary
-----------------
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo ART interruption.

Official Title
-----------------
A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART Interruption

Conditions
-----------------
HIV-1 Infection

Intervention / Treatment
-----------------
* Biological: UB-421
* Drug: chidamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-1 sero-positive, with documented HIV-1 infection by official, signed, written history Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg, aged 20 years or older. No breastfeeding or pregnancy for women. Have been receiving ART for more than 3 years by screening visit 1 (SV1). Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception Subjects must sign the informed consent before undergoing any study procedures. Exclusion Criteria: Subjects with active systemic infections, except for HIV-1 Any exposure to a monoclonal antibody within 12 weeks prior to the first dose of study drug. Current receiving treatment regimen for hepatitis B, hepatitis C or latent tuberculosis Any alcohol or illicit drug use Receipt of any other investigational study agent(s) within 90 days before SV2. Currently on the treatment for diabetes.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: UB-421 + chidamide<br>UB-421 + chidamide combination therapy | Biological: UB-421<br>* 10 mg/kg, weekly UB-421 during the 8-week<br>Drug: chidamide<br>* 10 mg/dose, twice a week for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HIV cell-associated RNA levels | The change in HIV-1 Total DNA from baseline after study drug administration. | Post-treatment weeks up to 48 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HIV-1 Total DNA levels | The changes in HIV-1 Total DNA levels during the study | Post-treatment weeks up to 48 weeks |
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Detailed Description
-----------------
Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long acting D2 agonist, is expected to play a role in the glycemic control.

Official Title
-----------------
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Drug: Cabergoline
* Drug: Gliclazide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients. Exclusion Criteria: Other drugs administration
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cabergoline<br>cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide | Drug: Cabergoline<br>* cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide<br>|
| Active Comparator: Gliclazide<br>gliclazide (60-120 mg) once daily | Drug: Gliclazide<br>* gliclazide (60-120 mg)<br>|
| No Intervention: Placebo<br>Placebo | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The level of fasting and post prandial BG level | Fasting and post prandial BG level will be measured after 4 months | 4 months |
Thermosoftening of Double-lumen Tube for Airway Exchanger Catheter

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of double-lumen tube thermal-softening before intubation on the success rate of tube exchange by airway exchange catheter.

Official Title
-----------------
Effect of Thermal-softening of Double-lumen Endobronchial Tubes on Success Rate of Airway Exchange Catheter

Conditions
-----------------
Intubation Complication, Hoarseness, Sore Throat

Intervention / Treatment
-----------------
* Procedure: non-thermosoftening
* Procedure: thermosoftening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing thoracic surgery that requires bronchoscopy study before the placement of double-lumen tubes Exclusion Criteria: Preoperative hoarseness or a sore throat History of upper airway diseases Anticipated difficult airway

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: non-thermosoftening<br>Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation. | Procedure: non-thermosoftening<br>* By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.<br>|
| Experimental: thermosoftening<br>Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation. | Procedure: thermosoftening<br>* By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubate | Length of time to exchange endotracheal tube from single- to double-lumen tube using airway exchange catheter. | Intraoperative (During exchanging single- to double-lumen tube) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative hoarseness (4-points scoring) |  | up to 48 hours after surgery | 
| postoperative sore throat (4-points scoring) |  | up to 48 hours after surgery | 
| Vocal cord injuries assessed by videolaryngoscope | vocal cord injuries observed after tube-exchange | up to 1 hour after double-lumen tube extubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
double-lumen tube, intubation, airway exchange catheter, thermosoftening
Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure prenatally with ultrasound the intratracheal flow volume displaced during breathing cycle in premature fetuses and to check whether a relationship exists between the inspired fluid and fetal lung maturation.

Official Title
-----------------
Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?

Conditions
-----------------
Fetal Lung Maturity

Intervention / Treatment
-----------------
* Device: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women delivering between 27 to 37 weeks. Women undergoing amniocentesis for determining fetal lung maturity between 27 to 37 weeks. Exclusion Criteria: Major fetal malformation. Oligohydramnios or rupture of membranes diagnosed before 24 weeks of gestation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Device: Ultrasound<br>* To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To check whether a threshold exists between peak velocity and/or volume of fluid inspired by the fetus and lung maturation. |  | end of the study |
A Dietary Intervention- Randomized Controlled Trial (DIRECT) Study; BGU-Harvard-Robarts Collaboration

Study Overview
=================
Brief Summary
-----------------
Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss

Detailed Description
-----------------
Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss

Conditions
-----------------
Obesity, CHD

Intervention / Treatment
-----------------
* Behavioral: dietary intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI>27 age>40 History of CHD or diabetes in any age or BMI level Exclusion Criteria: Pregnant or lactating women. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. Serum creatinine > 3 mg/dl. Liver dysfunction ( ³ 2 fold level of ALT and AST enzymes). Participation in another trial in which active intervention is being received. Any intestinal problem that would prevent the patient from eating one of the test diets (for example, gastric stapling that might prevent consumption of vegetables).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: dietary intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CVD mediators measurements |  |  |
Patient Registry of the Neurosurgery Department

Study Overview
=================
Brief Summary
-----------------
The investigators record all indications, treatments and outcomes from patients treated at the Neurosurgery Department. Trial with surgical intervention

Official Title
-----------------
Patient Registry of the Neurosurgery Department.

Conditions
-----------------
Patients Treated at the Neurosurgery Department

Intervention / Treatment
-----------------
* Procedure: Treatment at the neurosurgery departement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All patients treated at the Neurosurgery Department Exclusion criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated at the neurosurgery department<br>Patients treated at the neurosurgery department | Procedure: Treatment at the neurosurgery departement<br>* Treatment at the neurosurgery departement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurological outcome | validated scales like KPSS or NIHSS | 1 year | 
| social outcome | e.g. activity of daily living, employment status | 1 year |